ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016
Invasive candidiasis: from mycobiome to infection, therapy, and prevention.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Prognostic impact ofAnnals of intensive care · 2026Article
- In Vitro Evaluation of 5-Fluorouridine as an Adjuvant to Antifungal Drugs and Molecular Insights into Resistance to This Compound inInternational journal of molecular sciences · 2025Article
- The Prevalence and Drug Susceptibility ofAntibiotics (Basel, Switzerland) · 2025Article
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran:Antibiotics (Basel, Switzerland) · 2024Article
- Insights intoJournal of fungi (Basel, Switzerland) · 2024Article
- Biofilm Formation in Medically ImportantJournal of fungi (Basel, Switzerland) · 2023Review
- Invasive candidiasis: current clinical challenges and unmet needs in adult populations.The Journal of antimicrobial chemotherapy · 2023Review
- The Paradox of Prosthetic Joint Infection and the Microbiome: Are Some Bacteria Actually Helpful?Arthroplasty today · 2022Article
- Augmented Enterocyte Damage DuringFrontiers in cellular and infection microbiology · 2022Article
- Review
- Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages.Nature communications · 2021Article
- Comparative host transcriptome in response to pathogenic fungi identifies common and species-specific transcriptional antifungal host response pathways.Computational and structural biotechnology journal · 2021Article
- The pulmonary mycobiome-A study of subjects with and without chronic obstructive pulmonary disease.PloS one · 2021Observational
- Unambiguous determination of farnesol and tyrosol in vaginal fluid using fast and sensitive UHPLC-MS/MS method.Analytical and bioanalytical chemistry · 2020Article
- The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine.Current opinion in microbiology · 2020Review
- The Mycobiome in Health and Disease: Emerging Concepts, Methodologies and Challenges.Mycopathologia · 2020Review
- Risk factors for candidemia: a prospective matched case-control study.Critical care (London, England) · 2020Article
- Polymerase Chain Reaction Versus Blood Culture to Detect Candida Species in High-Risk Patients with Suspected Invasive Candidiasis: The MICAFEM Study.Infectious diseases and therapy · 2019Article
- Staged development of long-lived T-cell receptor αβ TThe Journal of allergy and clinical immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida spp. are commonly found in humans, colonizing most healthy individuals. A high prevalence of invasive candidiasis has been reported in recent years. Here, we assess the relation between Candida spp. as part of the human mycobiome, the host defense mechanisms, and the pathophysiology of invasive disease in critically ill patients. Many hypotheses have been proposed to explain the different immune responses to the process where Candida goes through healthy mycobiome to colonization to invasion; the involvement of other microbiota inhabitants, changes in temperature, low nitrogen levels, and the caspase system activation have been described. Patients admitted to an intensive care unit (ICU) are at the highest risk for invasive candidiasis, mostly due to the severity of their disease, immune-suppressive states, prolonged length of stay, broad-spectrum antibiotics, septic shock, and Candida colonization. The first approach should be using predictive scores as screening, followed by the determination of biomarkers (when available), and, in the near future, probably immune-genomics and analysis of the clinical background in order to initiate prompt and correct treatment. Regarding treatment, the initiation with an echinocandin is strongly recommended in critically ill patients. In conclusion, prompt treatment and adequate source control in the more severe patients remains the ultimate goal, as well as restoration of a healthy microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.